Cartesian Therapeutics (RNAC) Change in Cash (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Change in Cash data on file, last reported at -$6.5 million in Q1 2026.

• Change in Cash for Q1 2026 came in at -$6.5 million, up 79.8% year-over-year; the trailing twelve-month figure through Mar 2026 was -$61.7 million (down 179.85% YoY), and the FY2025 annual result was -$87.4 million, down 164.27% from the prior year.
• Change in Cash grew to -$6.5 million in Q1 2026 per RNAC's latest filing, from -$18.2 million in the prior quarter.
• Over five years, Change in Cash peaked at $132.0 million in Q3 2024 and troughed at -$34.0 million in Q3 2023.
• A 5-year average of $290588.2 and a median of -$6.6 million in 2024 frame the typical range for Change in Cash.
• On a YoY basis, Change in Cash climbed as much as 7098.83% in 2022 and fell as far as 989.29% in 2022.
• A 5-year view of Change in Cash shows it stood at -$6.4 million in 2022, then soared by 57.97% to -$2.7 million in 2023, then tumbled by 144.73% to -$6.6 million in 2024, then plunged by 176.94% to -$18.2 million in 2025, then jumped by 64.38% to -$6.5 million in 2026.
• Business Quant data shows RNAC's Change in Cash at -$6.5 million in Q1 2026, -$18.2 million in Q4 2025, and -$16.9 million in Q3 2025.